In our study, newly diagnosed T2DM patients with HbA1c > 9% and BMI ≥ 25 kg/m2 were treated either with oral Janumet (the experimental group) or insulin injection (the control group). This evidence concerns the gene INS and type 2 diabetes mellitus.